Momenta

Investor Relations

NASDAQ: MNTA
Price
11.77
Change
- 0.23
Day High
12.40
Day Low
11.71
Volume
320,500
4:00 PM ET on Aug 28, 2014
Stock price graph

Momenta Pharmaceuticals is a biotechnology company based in Cambridge, MA focused on the development of complex generics, follow-on biologics and novel drugs. In July 2010, the company's lead product (developed in collaboration with Sandoz) was approved as the first generic version of Lovenox® (enoxaparin sodium injection). The company’s development pipeline includes a generic version of Copaxone® (glatiramer acetate), also in collaboration with Sandoz, follow-on biologics in collaboration with Baxter, and necuparanib (formerly M402), a novel oncology drug candidate currently undergoing testing in early phase human clinical trials. Necuparanib has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.

View Annual Report and Proxy Material

View all »   RSSRecent Releases

Aug 28, 2014
Momenta Pharmaceuticals Announces Abbreviated New Drug Application for Three-Times-a-Week Generic Copaxone Accepted for Review by FDA

Jul 31, 2014
Momenta Pharmaceuticals Reports Second Quarter 2014 Financial Results

Last Revised 6/12/2012